LLY Jan 2025 360.000 call

UPDATE 1-US FDA panel to discuss Eli Lilly Alzheimer's drug on June 10

Eli Lilly said on Tuesday a panel of independent U.S. FDA advisers will discuss whether the agency should approve its Alzheimer's disease drug, donanemab, on June 10. A possible approval for donanemab would pit it against a similar therapy by Eisai and partner Biogen, called Leqembi, which received the U.S. Food and Drug Administration's approval last year. Donanemab has faced two separate regulatory delays in the United States, one in January 2023, after the FDA declined accelerated approval, and another on March 8, when the agency said it would hold a meeting of its advisers to discuss the drug.